Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p

References

• Thomson PJ. Perspectives on oral squamous cell carcinoma prevention-proliferation, position, progression and prediction. J Oral Pathol Med. 2018;47(9):803–807.29752860
   PubMed Web of Science ®Google Scholar
• Eguchi T, Basugi A, Kanai I, Miyata Y, Suzuki T, Hamada Y. Adenosquamous carcinoma development as a recurrence of squamous cell carcinoma in the oral floor: a case report. Medicine. 2019;98(43):e17688.31651897
   PubMed Web of Science ®Google Scholar
• Gawas NP, Navarange SS, Chovatiya GL, Chaturvedi P, Waghmare SK. Establishment and characterization of novel human oral squamous cell carcinoma cell lines from advanced‑stage tumors of buccal mucosa. Oncol Rep. 2019;41(4):2289–2298.30816493
   PubMed Web of Science ®Google Scholar
• Panarese I, Aquino G, Ronchi A, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019;19(2):105–119.30582397
   PubMed Web of Science ®Google Scholar
• Bharadwaj R, Sahu BP, Haloi J, et al. Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):572–585.30831033
   PubMed Web of Science ®Google Scholar
• Liu T, David M, Ellis O, et al. Treatment for oral squamous cell carcinoma: impact of surgeon volume on survival. Oral Oncol. 2019;96:60–65.31422214
   PubMed Web of Science ®Google Scholar
• Mroueh R, Haapaniemi A, Saarto T, et al. Non-curative treatment of patients with oral tongue squamous-cell carcinoma. Eur Arch Otorhinolaryngol. 2019;276(7):2039–2045.31069467
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu Y, Xiao W, et al. MicroRNA-299-3p/FOXP4 axis regulates the proliferation and migration of oral squamous cell carcinoma. Technol Cancer Res Treat. 2019;18:1533033819874803.31500519
   PubMed Web of Science ®Google Scholar
• Wang J, Huo F, Wang XR, Xu YY. LncRNA LACAT1 promotes proliferation of oral squamous cell carcinoma cells by inhibiting microRNA-4301. Eur Rev Med Pharmacol Sci. 2019;23(6):2427–2435.30964168
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng X, Zhu XW, et al. Long non-coding RNAs in oral squamous cell carcinoma: biologic function, mechanisms and clinical implications. Mol Cancer. 2019;18(1):102.31133028
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo B, Zhu Y, Xu W, Ning S, Liu L. Up-regulation of plasma lncRNA CACS15 distinguished early-stage oral squamous cell carcinoma patient. Oral Dis. 2019;1:2145.
   Google Scholar
• Yu Y, Dong JT, He B, et al. LncRNA SNHG16 induces the SREBP2 to promote lipogenesis and enhance the progression of pancreatic cancer. Future Oncol. 2019;15(33):3831–3844.31664866
   PubMed Web of Science ®Google Scholar
• Zhou C, Zhao J, Liu J, et al. LncRNA SNHG16 promotes epithelial-mesenchymal transition via down-regulation of DKK3 in gastric cancer. Cancer Biomark. 2019;26(4):393–401.31561329
   PubMed Web of Science ®Google Scholar
• Cao X, Xu J, Yue D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther. 2018;25(1–2):10–17.29234154
   PubMed Web of Science ®Google Scholar
• Li S, Zhang S, Chen J. c-Myc induced upregulation of long non-coding RNA SNHG16 enhances progression and carcinogenesis in oral squamous cell carcinoma. Cancer Gene Ther. 2019;26(11–12):400–410.30607006
   PubMed Web of Science ®Google Scholar
• Correia De Sousa M, Gjorgjieva M, Dolicka D. Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci. 2019;20:24.
   Web of Science ®Google Scholar
• Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 2019;21(2):126–144.29951892
   PubMed Web of Science ®Google Scholar
• Chamorro Petronacci CM, Pérez-Sayáns M, Padín Iruegas ME, Suárez Peñaranda JM, Lorenzo Pouso AI, Blanco Carrión A. and García García A, miRNAs expression of oral squamous cell carcinoma patients: validation of two putative biomarkers. Medicine. 2019;98(13):e14922.30921188
   PubMed Web of Science ®Google Scholar
• Lu Z, He Q, Liang J, et al. miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer. Mol Ther Nucleic Acids. 2019;16:471–480.31051332
   PubMedGoogle Scholar
• Zhao J, Fang Z, Zha Z, et al. Quercetin inhibits cell viability, migration and invasion by regulating miR-16/HOXA10 axis in oral cancer. Eur J Pharmacol. 2019;847:11–18.30639311
   PubMed Web of Science ®Google Scholar
• Coutinho-Camillo CM, Lourenço SV, de Araújo Lima L, Kowalski LP, Soares FA. Expression of apoptosis-regulating miRNAs and target mRNAs in oral squamous cell carcinoma. Cancer Genet. 2015;208(7–8):382–389.26027785
   PubMed Web of Science ®Google Scholar
• Wu SY, Lin KC, Chiou JF, et al. MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells. Strahlenther Onkol. 2013;189(8):675–683.23780339
   PubMed Web of Science ®Google Scholar
• Wu SY, Wu AT, Liu SH. MicroRNA-17-5p regulated apoptosis-related protein expression and radiosensitivity in oral squamous cell carcinoma caused by betel nut chewing. Oncotarget. 2016;7(32):51482–51493.27285985
   PubMedGoogle Scholar
• Li J, Lai Y, Ma J, et al. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. BMC Cancer. 2017;17(1):745.29126392
   PubMed Web of Science ®Google Scholar
• Cai N, Hu L, Xie Y, et al. MiR-17-5p promotes cervical cancer cell proliferation and metastasis by targeting transforming growth factor-β receptor 2. Eur Rev Med Pharmacol Sci. 2018;22(7):1899–1906.29687841
   PubMed Web of Science ®Google Scholar
• Tam C, Wong JH, Tsui SKW, Zuo T, Chan TF, Ng TB. LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years. Appl Microbiol Biotechnol. 2019;103(12):4649–4677.31062053
   PubMed Web of Science ®Google Scholar
• Tang F, Lu Z, Wang J, et al. Competitive endogenous RNA (ceRNA) regulation network of lncRNAs, miRNAs, and mRNAs in Wilms tumour. BMC Med Genomics. 2019;12(1):194.31842887
   PubMed Web of Science ®Google Scholar
• Peng H, Li H. The encouraging role of long noncoding RNA small nuclear RNA host gene 16 in epithelial-mesenchymal transition of bladder cancer via directly acting on miR-17-5p/metalloproteinases 3 axis. Mol Carcinog. 2019;58(8):1465–1480.31026378
   PubMed Web of Science ®Google Scholar
• Chen G, Ding XF, Bouamar H, Pressley K, Sun LZ. Everolimus induces G(1) cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells. Am J Physiol Cell Physiol. 2019;317(2):C244–c252.31116586
   PubMed Web of Science ®Google Scholar
• Sun F, Li N, Tong X, et al. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1. Cell Cycle. 2019;18(18):2293–2306.31322047
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang H, Liu T, et al. 6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3β-cyclin D1 pathway in renal-cell carcinoma. Cancer Chemother Pharmacol. 2020;85(2):379–390.31832810
   PubMed Web of Science ®Google Scholar
• Albasri AM, Elkablawy MA, Ansari IA, Alhujaily AS. Prognostic significance of Cyclin D1 over-expression in colorectal cancer: an experience from Madinah, Saudi Arabia. Asian Pac J Cancer Prev. 2019;20(8):2471–2476.31450922
   PubMedGoogle Scholar
• Choi C, Park S, Cho WK, Choi DH. Cyclin D1 is associated with radiosensitivity of triple-negative breast cancer cells to proton beam irradiation. Int J Mol Sci. 2019;20:19.
   Web of Science ®Google Scholar
• Kujan O, Huang G, Ravindran A, Vijayan M, Farah CS. CDK4, CDK6, cyclin D1 and Notch1 immunocytochemical expression of oral brush liquid-based cytology for the diagnosis of oral leukoplakia and oral cancer. J Oral Pathol Med. 2019;48(7):566–573.31172614
   PubMed Web of Science ®Google Scholar
• Ramos-García P, González-Moles M, González-Ruiz L, et al. Clinicopathological significance of tumor cyclin D1 expression in oral cancer. Arch Oral Biol. 2019;99:177–182.30721793
   PubMed Web of Science ®Google Scholar
• Gan CP, Sam KK, Yee PS, et al. IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells. Cell Oncol. 2019;42(4):477–490.
   Web of Science ®Google Scholar
• Liu L, Li J, Wang R, Wang Y, Wang G. MicroRNA-298 exacerbates myocardial ischemic injury via targeting cyclin D1. Pharmazie. 2019;74(6):369–373.31138376
   PubMed Web of Science ®Google Scholar
• Sun W, Lv J, Duan L, et al. Long noncoding RNA H19 promotes vascular remodeling by sponging let-7a to upregulate the expression of cyclin D1. Biochem Biophys Res Commun. 2019;508(4):1038–1042.30551879
   PubMed Web of Science ®Google Scholar
• Wang F, Mao A, Tang J, et al. microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells. J Cell Physiol. 2019;234(8):13182–13190.30536619
   PubMed Web of Science ®Google Scholar
• Liang W, Sun F. Identification of pivotal lncRNAs in papillary thyroid cancer using lncRNA-mRNA-miRNA ceRNA network analysis. PeerJ. 2019;7:e7441.31579562
   PubMed Web of Science ®Google Scholar
• Tang XJ, Wang W, Hann SS. Interactions among lncRNAs, miRNAs and mRNA in colorectal cancer. Biochimie. 2019;163:58–72.31082429
   PubMed Web of Science ®Google Scholar
• Santarelli A, Mascitti M, Rubini C, et al. Nuclear survivin as a prognostic factor in squamous-cell carcinoma of the oral cavity. Appl Immunohistochem Mol Morphol. 2017;25(8):566–570.27389554
   PubMedGoogle Scholar